# OnCo record pancreatic (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/pancreatic/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "pancreatic" ;
  schema:name "Pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "Pancreatic cancer"@en, "PDAC"@en, "Cancer of the pancreas"@en, "Exocrine pancreatic cancer"@en, "Pancreatic adenocarcinoma"@en ;
  schema:description "Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."@en ;
  schema:url <https://onco.cc/cancers/pancreatic/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q212961> ;
  schema:citation <https://en.wikipedia.org/wiki/Pancreatic_cancer>, <https://gco.iarc.who.int/media/globocan/factsheets/cancers/13-pancreas-fact-sheet.pdf>, <https://seer.cancer.gov/statfacts/html/pancreas.html>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/incidence>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/mortality>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/survival>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/risk-factors>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/stages-types-grades/types>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/symptoms>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/stages-types-grades/tnm-staging>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/stages-types-grades>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/getting-diagnosed/tests>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/getting-diagnosed/screening>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/risks-causes>, <https://www.nhs.uk/conditions/pancreatic-cancer/>, <https://www.nhs.uk/conditions/pancreatic-cancer/causes/>, <https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455>, <https://doi.org/10.1001/jamanetworkopen.2021.4708>, <https://doi.org/10.1053/j.gastro.2020.10.007>, <https://doi.org/10.1038/s41575-021-00457-x>, <https://doi.org/10.1097/mpa.0000000000000392>, <https://doi.org/10.1093/annonc/mdr541>, <https://doi.org/10.1002/ijc.25794>, <https://doi.org/10.1038/sj.bjc.6602619>, <https://doi.org/10.1016/j.ejca.2011.03.003>, <https://doi.org/10.1038/ajg.2017.218>, <https://doi.org/10.1158/0008-5472.can-03-3823>, <https://doi.org/10.1001/jama.2018.6228>, <https://doi.org/10.1200/jco.2017.72.3502>, <https://doi.org/10.1053/j.gastro.2005.05.007>, <https://doi.org/10.1053/j.gastro.2008.01.039>, <https://doi.org/10.1016/j.pan.2012.02.003>, <https://doi.org/10.1053/j.gastro.2018.05.023>, <https://doi.org/10.1016/s2468-1253(16)30079-6>, <https://doi.org/10.1038/bjc.2012.408>, <https://doi.org/10.1038/s41416-026-03343-y>, <https://doi.org/10.1148/radiol.13131184>, <https://doi.org/10.1016/j.pan.2017.11.011>, <https://doi.org/10.6004/jnccn.2021.0017>, <https://doi.org/10.1097/sla.0000000000001763>, <https://doi.org/10.1245/s10434-017-5810-x>, <https://doi.org/10.3978/j.issn.2078-6891.2011.021>, <https://doi.org/10.1016/j.pan.2018.08.003>, <https://doi.org/10.1002/bjs.5397>, <https://doi.org/10.1245/s10434-008-9839-8>, <https://doi.org/10.1111/j.1365-2559.2009.03376.x>, <https://doi.org/10.1097/sla.0000000000001731>, <https://doi.org/10.1097/sla.0000000000002557>, <https://doi.org/10.1097/00000478-200105000-00003>, <https://doi.org/10.1097/pas.0000000000000533>, <https://doi.org/10.1097/mpa.0000000000000786>, <https://doi.org/10.1136/gutjnl-2016-313127>, <https://doi.org/10.1111/his.13975>, <https://doi.org/10.1136/gutjnl-2019-319352>, <https://doi.org/10.1053/j.gastro.2018.05.035>, <https://doi.org/10.1200/jco.22.00298>, <https://doi.org/10.1136/gutjnl-2020-323611>, <https://doi.org/10.1200/jco.22.00194>, <https://doi.org/10.1038/s41395-018-0395-y>, <https://doi.org/10.1053/j.gastro.2021.08.036>, <https://doi.org/10.1001/jama.2019.10232>, <https://doi.org/10.1016/s2468-1253(19)30416-9>, <https://doi.org/10.1634/theoncologist.2018-0266>, <https://doi.org/10.1007/s11605-008-0505-z>, <https://www.nice.org.uk/guidance/ng85/chapter/Recommendations>, <https://www.natcan.org.uk/reports/npaca-state-of-the-nation-report-2026/>, <https://www.pancreaticcancer.org.uk/>, <https://www.nhs.uk/conditions/pancreatic-cancer/symptoms/>, <https://www.nhs.uk/conditions/pancreatic-cancer/tests-and-next-steps/>, <https://www.nhs.uk/conditions/pancreatic-cancer/treatment/>, <https://www.nhs.uk/conditions/pancreatic-cancer/help-and-support/>, <https://www.nice.org.uk/guidance/ta476/chapter/1-Recommendations>, <https://www.nice.org.uk/guidance/ta440/chapter/1-Recommendations>, <https://www.nice.org.uk/guidance/terminated/ta750>, <https://www.pancreaticcancer.org.uk/information-and-support/just-diagnosed-with-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/just-diagnosed-with-pancreatic-cancer/if-you-cant-have-surgery-inoperable-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/surgery-for-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/chemotherapy/how-is-chemotherapy-used-for-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/diet-and-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/diet-and-pancreatic-cancer/pancreatic-enzyme-replacement-therapy-pert/how-do-i-take-pancreatic-enzyme-replacement-therapy-if-i-have-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/diabetes-with-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/managing-pancreatic-cancer-pain/>, <https://www.pancreaticcancer.org.uk/information-and-support/managing-symptoms-and-side-effects/managing-jaundice-if-you-have-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/dealing-with-pancreatic-cancer/dealing-with-the-emotional-impact-of-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/dealing-with-pancreatic-cancer/daily-life-with-pancreatic-cancer/work-and-money/>, <https://www.pancreaticcancer.org.uk/information-and-support/support-for-you/information-for-family-members/>, <https://www.pancreaticcancer.org.uk/information-and-support/family-history-of-pancreatic-cancer/>, <https://www.pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer/current-developments-in-pancreatic-cancer-treatment/>, <https://www.macmillan.org.uk/cancer-information-and-support/pancreatic-cancer/controlling-symptoms-of-pancreatic-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemotherapy-for-pancreatic-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/pancreatic-cancer/types-of-surgery-for-pancreatic-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatment/your-treatment-options/questions-to-ask-your-healthcare-team>, <https://www.macmillan.org.uk/cancer-information-and-support/treatment/if-you-have-an-advanced-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/olaparib>, <https://www.macmillan.org.uk/cancer-information-and-support/worried-about-cancer/causes-and-risk-factors/brca-gene>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/treatment-decisions>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/surgery>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/chemotherapy>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/about-radiotherapy>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/controlling-symptoms>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/follow-up-appointment>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/living-with/diet>, <https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/living-with/coping>, <https://www.esmo.org/for-patients/patient-guides/pancreatic-cancer>, <https://www.mariecurie.org.uk/information/getting-care/palliative-care>, <https://doi.org/10.1056/NEJMoa1011923>, <https://doi.org/10.1056/NEJMoa1304369>, <https://doi.org/10.1016/S0140-6736(23)01366-1>, <https://doi.org/10.1056/NEJMoa1809775>, <https://doi.org/10.1016/S0140-6736(16)32409-6>, <https://doi.org/10.1056/NEJMoa1903387>, <https://doi.org/10.1200/JCO.21.02233>, <https://doi.org/10.1200/JCO.2010.32.2750>, <https://doi.org/10.1016/j.pan.2018.10.010>, <https://doi.org/10.1136/bmjgast-2021-000643>, <https://doi.org/10.1016/j.surg.2018.01.024>, <https://doi.org/10.1200/JCO.20.00611>, <https://www.nhs.uk/tests-and-treatments/clinical-trials/>, <https://www.nhs.uk/tests-and-treatments/genetic-and-genomic-testing/>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/sepsis>, <https://www.macmillan.org.uk/cancer-information-and-support/supporting-someone/looking-after-someone-with-cancer> ;
  onco:tag "gi", "spike" ;
  onco:related <https://onco.cc/roadmaps/kras-roadmap/>, <https://onco.cc/roadmaps/early-detection-roadmap/>, <https://onco.cc/collections/pancan/>, <https://onco.cc/ideas/idea-drugging-myc/>, <https://onco.cc/ideas/idea-nerve-tumour-blockade/>, <https://onco.cc/cancers/pancreatic-adenosquamous-carcinoma/>, <https://onco.cc/cancers/pancreatic-colloid-carcinoma/>, <https://onco.cc/cancers/pancreatic-undifferentiated-carcinoma-ogc/>, <https://onco.cc/cancers/ipmn-associated-carcinoma/>, <https://onco.cc/cancers/mcn-associated-carcinoma/>, <https://onco.cc/cancers/solid-pseudopapillary-neoplasm/>, <https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/>, <https://onco.cc/cancers/ipmn-cystic-precursors/>, <https://onco.cc/cancers/pancreatoblastoma/>, <https://onco.cc/cancers/pancreatic-net/>, <https://onco.cc/cancers/ampullary/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/roadmaps/pancreatic-roadmap/>, <https://onco.cc/ideas/idea-pdac-new-onset-diabetes-risk-score-pathway/>, <https://onco.cc/ideas/idea-pdac-surveillance-for-every-germline-carrier/>, <https://onco.cc/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/>, <https://onco.cc/ideas/idea-pdac-stromal-reprogramming-not-depletion/>, <https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/>, <https://onco.cc/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/>, <https://onco.cc/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/>, <https://onco.cc/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/>, <https://onco.cc/ideas/idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway/>, <https://onco.cc/biomarkers/kras-g12d/>, <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/biomarkers/tmb-high/>, <https://onco.cc/biomarkers/brca-germline/>, <https://onco.cc/biomarkers/brca-somatic/>, <https://onco.cc/biomarkers/hrd-positive/>, <https://onco.cc/biomarkers/ctdna-mrd-positive/>, <https://onco.cc/biomarkers/alk-fusion/>, <https://onco.cc/biomarkers/ntrk-fusion/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/ttfields/>, <https://onco.cc/technologies/fapi-pet/>, <https://onco.cc/technologies/mced/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/irreversible-electroporation/>, <https://onco.cc/technologies/omega3-epa-cachexia/>, <https://onco.cc/technologies/mistletoe-extracts/>, <https://onco.cc/technologies/gerson-therapy-detox-regimens/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/mr-linac/>, <https://onco.cc/technologies/shared-antigen-vaccine/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/technologies/pdac-organoid-pharmacotyping/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/staging-laparoscopy/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/enteral-parenteral-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/cancer-associated-thrombosis/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/msi-mmr-testing/>, <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/technologies/single-cell-spatial/>, <https://onco.cc/technologies/spatial-transcriptomics/>, <https://onco.cc/technologies/organoids/>, <https://onco.cc/technologies/proteomics/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/cfdna-methylation-testing/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/targets/fap/>, <https://onco.cc/targets/mesothelin/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/nrg1/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/cdkn2a/>, <https://onco.cc/targets/smad4/>, <https://onco.cc/targets/palb2/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/mmr/>, <https://onco.cc/targets/gnas/>, <https://onco.cc/targets/rnf43/>, <https://onco.cc/targets/kdm6a/>, <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/arid1a/>, <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/catumaxomab/>, <https://onco.cc/drugs/tegafur-gimeracil-oteracil/>, <https://onco.cc/drugs/pancrelipase/>, <https://onco.cc/drugs/pegvorhyaluronidase-alfa/>, <https://onco.cc/drugs/pegilodecakin/>, <https://onco.cc/drugs/napabucasin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/leucovorin/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/elraglusib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/ponsegromab/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/caris-mi-cancer-seek/>, <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/trusight-oncology-comprehensive/>, <https://onco.cc/drugs/tempus-xt-cdx/>, <https://onco.cc/drugs/bracanalysis-cdx/>, <https://onco.cc/drugs/ventana-mmr-rxdx/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/galleri/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/crizotinib/> ;
  onco:companies <https://onco.cc/companies/marker-therapeutics/>, <https://onco.cc/companies/orion-orion-pharma/>, <https://onco.cc/companies/crinetics-pharmaceuticals/>, <https://onco.cc/companies/oncolytics-biotech/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/ascentawits-pharmaceuticals/>, <https://onco.cc/companies/cebiotex/>, <https://onco.cc/companies/civatech-oncology/>, <https://onco.cc/companies/mbrace-therapeutics/>, <https://onco.cc/companies/molecular-partners/>, <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/ipsen/>, <https://onco.cc/companies/novocure/>, <https://onco.cc/companies/biontech/>, <https://onco.cc/companies/elicio-therapeutics/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/carsgen/>, <https://onco.cc/companies/bms/> ;
  onco:institutions <https://onco.cc/institutions/pancreatic-cancer-uk/>, <https://onco.cc/institutions/pancreatic-cancer-action/>, <https://onco.cc/institutions/wolfson-wohl-cancer-research-centre/>, <https://onco.cc/institutions/liverpool-hpb-centre/>, <https://onco.cc/institutions/glasgow-royal-infirmary/>, <https://onco.cc/institutions/hull-castle-hill/>, <https://onco.cc/institutions/royal-stoke-uhnm/>, <https://onco.cc/institutions/uhcw-coventry/>, <https://onco.cc/institutions/royal-surrey-guildford/>, <https://onco.cc/institutions/royal-blackburn-elht/>, <https://onco.cc/institutions/ninewells-dundee/>, <https://onco.cc/institutions/aberdeen-royal-infirmary/>, <https://onco.cc/institutions/raigmore-inverness/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/emt/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/tgf-beta/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/swi-snf-chromatin/>, <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/mutagenesis-signatures/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/chromosomal-instability/>, <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/pathways/caf-activation-desmoplasia/>, <https://onco.cc/pathways/immune-desert-exclusion/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/tumor-microenvironment/>, <https://onco.cc/pathways/hedgehog/>, <https://onco.cc/pathways/autophagy/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/epigenetic-reprogramming/> ;
  onco:terms <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/desmoplasia/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/hazard-ratio/>, <https://onco.cc/terms/nccn-resectability-criteria-pancreatic/>, <https://onco.cc/terms/pancreas-protocol-ct/>, <https://onco.cc/terms/distal-pancreatectomy/>, <https://onco.cc/terms/vascular-resection-pancreatic/>, <https://onco.cc/terms/pancreatic-enzyme-replacement/>, <https://onco.cc/terms/lewis-negative/>, <https://onco.cc/terms/panin/>, <https://onco.cc/terms/pancreatic-cyst-high-risk-stigmata/>, <https://onco.cc/terms/new-onset-diabetes-pancreatic-cancer/>, <https://onco.cc/terms/r0-r1-margin-pancreatic/>, <https://onco.cc/terms/neoadjuvant-versus-upfront-surgery-pancreatic/>, <https://onco.cc/terms/emergency-presentation/>, <https://onco.cc/terms/familial-pancreatic-cancer/>, <https://onco.cc/terms/classical-vs-basal-like/>, <https://onco.cc/terms/clinical-benefit-response/>, <https://onco.cc/terms/type-3c-diabetes-pancreatic-cancer/>, <https://onco.cc/terms/coeliac-plexus-block/>, <https://onco.cc/terms/eating-after-whipple/>, <https://onco.cc/terms/chemotherapy-side-effects-pancreatic/>, <https://onco.cc/terms/urgent-help-pancreatic-cancer/>, <https://onco.cc/terms/work-and-money-pancreatic-cancer-uk/>, <https://onco.cc/terms/carers-pancreatic-cancer-uk/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/terms/locally-advanced/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/stage-shift/>, <https://onco.cc/terms/sarcopenia/>, <https://onco.cc/terms/stent-or-bypass-for-jaundice/>, <https://onco.cc/terms/biliary-stent-problems/>, <https://onco.cc/terms/acute-cholangitis/>, <https://onco.cc/terms/jaundice-and-itch-biliary/>, <https://onco.cc/terms/duodenal-stenting-gastric-outlet/>, <https://onco.cc/terms/nutrition-impact-symptoms/>, <https://onco.cc/terms/peripheral-neuropathy/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/hand-foot-syndrome/>, <https://onco.cc/terms/mucositis/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/vte/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/emotional-support-cancer-uk/>, <https://onco.cc/terms/malnutrition-screening/>, <https://onco.cc/terms/total-neoadjuvant-therapy/>, <https://onco.cc/terms/tumour-markers/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/biliary-stent/>, <https://onco.cc/terms/ppv/>, <https://onco.cc/terms/pancreatic-trials-open-today/>, <https://onco.cc/terms/pancreatic-palliation-obstruction-pain-nutrition/>, <https://onco.cc/terms/pancreatic-cancer-uk-drug-access/>, <https://onco.cc/terms/pancreatic-failed-programmes/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/terms/gata6-classical-basal-marker/>, <https://onco.cc/terms/kras-allelic-imbalance/>, <https://onco.cc/terms/caf-subtypes-pancreatic/>, <https://onco.cc/terms/compass-study-pancreatic/>, <https://onco.cc/terms/caps-consortium-pancreatic-screening/>, <https://onco.cc/terms/detect-a-study/>, <https://onco.cc/terms/ccga-study/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/cfdna/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/wild-type/>, <https://onco.cc/terms/mutational-signature/>, <https://onco.cc/terms/immune-exclusion/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/whole-genome-doubling/>, <https://onco.cc/terms/copy-number-variation-term/>, <https://onco.cc/terms/hereditary-cancer-syndromes/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/founder-mutation/>, <https://onco.cc/terms/somatic-mutations-wxs-wgs/>, <https://onco.cc/terms/tumour-informed-assay/>, <https://onco.cc/terms/vus/> ;
  onco:trials <https://onco.cc/trials/mountaintap-30/>, <https://onco.cc/trials/nct06608927/>, <https://onco.cc/trials/nct07262567/>, <https://onco.cc/trials/nct07409272/>, <https://onco.cc/trials/nct07522073/>, <https://onco.cc/trials/nct06079346/>, <https://onco.cc/trials/nct07079228/>, <https://onco.cc/trials/nct05254171/>, <https://onco.cc/trials/nct07562152/>, <https://onco.cc/trials/g-hope-002/>, <https://onco.cc/trials/nct01954992/>, <https://onco.cc/trials/notable-trial/>, <https://onco.cc/trials/nct07491445/>, <https://onco.cc/trials/nct07219238/>, <https://onco.cc/trials/nct07805954/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct07621718/>, <https://onco.cc/trials/nct04969731/>, <https://onco.cc/trials/nct06361888/>, <https://onco.cc/trials/nct03257033/>, <https://onco.cc/trials/nct06953999/>, <https://onco.cc/trials/nct07165886/>, <https://onco.cc/trials/nct06784752/>, <https://onco.cc/trials/nct05653453/>, <https://onco.cc/trials/nct03972488/>, <https://onco.cc/trials/nct06861088/>, <https://onco.cc/trials/nct07232875/>, <https://onco.cc/trials/nct06752811/>, <https://onco.cc/trials/nct07087054/>, <https://onco.cc/trials/nct07823049/>, <https://onco.cc/trials/nct05884255/>, <https://onco.cc/trials/nct07238283/>, <https://onco.cc/trials/nct03899636/>, <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/trials/napoli-3/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/polo/>, <https://onco.cc/trials/panova-3/>, <https://onco.cc/trials/amplify-7p/>, <https://onco.cc/trials/europac/>, <https://onco.cc/trials/precede/>, <https://onco.cc/trials/precision-panc/>, <https://onco.cc/trials/espac-4/>, <https://onco.cc/trials/espac-5/>, <https://onco.cc/trials/conko-001/>, <https://onco.cc/trials/lap07/>, <https://onco.cc/trials/nct05968326/>, <https://onco.cc/trials/espac-1/>, <https://onco.cc/trials/jaspac-01/>, <https://onco.cc/trials/apact/>, <https://onco.cc/trials/swog-s1505/>, <https://onco.cc/trials/neonax/>, <https://onco.cc/trials/preopanc-2/>, <https://onco.cc/trials/alliance-a021806/>, <https://onco.cc/trials/preopanc-3/>, <https://onco.cc/trials/alliance-a021501/>, <https://onco.cc/trials/conko-005/>, <https://onco.cc/trials/autogene-cevumeran-phase-1/>, <https://onco.cc/trials/starpac2/>, <https://onco.cc/trials/primus-001/>, <https://onco.cc/trials/prodige-4-accord-11/>, <https://onco.cc/trials/mpact/>, <https://onco.cc/trials/napoli-1/>, <https://onco.cc/trials/conko-003/>, <https://onco.cc/trials/panoptimox-prodige-35/>, <https://onco.cc/trials/conko-007/>, <https://onco.cc/trials/neolap/>, <https://onco.cc/trials/scalop/>, <https://onco.cc/trials/scalop-2/>, <https://onco.cc/trials/crossfire/>, <https://onco.cc/trials/panfire-2/>, <https://onco.cc/trials/halo-301/>, <https://onco.cc/trials/sequoia/>, <https://onco.cc/trials/canstem111p/>, <https://onco.cc/trials/resolve/>, <https://onco.cc/trials/codebreak-100/>, <https://onco.cc/trials/eclipse/>, <https://onco.cc/trials/espac-3/>, <https://onco.cc/trials/norpact-1/>, <https://onco.cc/trials/nct03785249/>, <https://onco.cc/trials/nct02912949/>, <https://onco.cc/trials/nct05379985/>, <https://onco.cc/trials/keynote-158/>, <https://onco.cc/trials/precision-promise/>, <https://onco.cc/trials/actuate-1801/>, <https://onco.cc/trials/avenger-500/>, <https://onco.cc/trials/lapis-trial/>, <https://onco.cc/trials/trybeca-1/>, <https://onco.cc/trials/impress-trial/>, <https://onco.cc/trials/nct05737706/>, <https://onco.cc/trials/nct06989437/> ;
  onco:people <https://onco.cc/people/randy-pausch/>, <https://onco.cc/people/daniel-von-hoff/>, <https://onco.cc/people/andrew-biankin/>, <https://onco.cc/people/paula-ghaneh/>, <https://onco.cc/people/daniel-palmer/>, <https://onco.cc/people/chris-halloran/>, <https://onco.cc/people/bill-greenhalf/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/>, <https://onco.cc/key-papers/paper-rahib-projecting-cancer-deaths-2030-cancerres-2014/>, <https://onco.cc/key-papers/paper-jones-pancreatic-core-pathways-science-2008/>, <https://onco.cc/key-papers/paper-biankin-pancreatic-exomes-axon-guidance-nature-2012/>, <https://onco.cc/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/>, <https://onco.cc/key-papers/paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017/>, <https://onco.cc/key-papers/paper-collisson-pancreatic-subtypes-nat-med-2011/>, <https://onco.cc/key-papers/paper-aung-compass-early-results-ccr-2018/>, <https://onco.cc/key-papers/paper-okane-gata6-basal-like-compass-ccr-2020/>, <https://onco.cc/key-papers/paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020/>, <https://onco.cc/key-papers/paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020/>, <https://onco.cc/key-papers/paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018/>, <https://onco.cc/key-papers/paper-topham-subtype-discordant-pancreatic-ccr-2021/>, <https://onco.cc/key-papers/paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020/>, <https://onco.cc/key-papers/paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018/>, <https://onco.cc/key-papers/paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/>, <https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/>, <https://onco.cc/key-papers/paper-singhi-alk-rearrangements-pancreatic-jnccn-2017/>, <https://onco.cc/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/>, <https://onco.cc/key-papers/paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021/>, <https://onco.cc/key-papers/paper-shindo-germline-sporadic-pancreatic-jco-2017/>, <https://onco.cc/key-papers/paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019/>, <https://onco.cc/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/>, <https://onco.cc/key-papers/paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016/>, <https://onco.cc/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/>, <https://onco.cc/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/>, <https://onco.cc/key-papers/paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021/>, <https://onco.cc/key-papers/paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017/>, <https://onco.cc/key-papers/paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018/>, <https://onco.cc/key-papers/paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016/>, <https://onco.cc/key-papers/paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009/>, <https://onco.cc/key-papers/paper-crane-smad4-progression-pattern-locally-advanced-jco-2011/>, <https://onco.cc/key-papers/paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010/>, <https://onco.cc/key-papers/paper-notta-punctuated-evolution-pancreatic-nature-2016/>, <https://onco.cc/key-papers/paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017/>, <https://onco.cc/key-papers/paper-makohon-moore-precursor-cells-ductal-system-nature-2018/>, <https://onco.cc/key-papers/paper-hruban-panin-nomenclature-ajsp-2001/>, <https://onco.cc/key-papers/paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015/>, <https://onco.cc/key-papers/paper-kanda-panin-1-somatic-mutations-gastroenterology-2012/>, <https://onco.cc/key-papers/paper-wu-gnas-ipmn-sci-transl-med-2011/>, <https://onco.cc/key-papers/paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011/>, <https://onco.cc/key-papers/paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015/>, <https://onco.cc/key-papers/paper-omori-ipmn-progression-pathways-gastroenterology-2019/>, <https://onco.cc/key-papers/paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018/>, <https://onco.cc/key-papers/paper-noe-cyst-malignant-progression-genomics-nat-commun-2020/>, <https://onco.cc/key-papers/paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009/>, <https://onco.cc/key-papers/paper-rhim-stroma-restrains-pancreatic-cancer-cell-2014/>, <https://onco.cc/key-papers/paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017/>, <https://onco.cc/key-papers/paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019/>, <https://onco.cc/key-papers/paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013/>, <https://onco.cc/key-papers/paper-grunwald-subtme-pancreatic-cell-2021/>, <https://onco.cc/key-papers/paper-royal-ipilimumab-pancreatic-j-immunother-2010/>, <https://onco.cc/key-papers/paper-brahmer-anti-pd-l1-phase-1-nejm-2012/>, <https://onco.cc/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/>, <https://onco.cc/key-papers/paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017/>, <https://onco.cc/key-papers/paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020/>, <https://onco.cc/key-papers/paper-ho-pancreatic-tumour-microenvironment-review-nrco-2020/>, <https://onco.cc/key-papers/paper-goonetilleke-ca19-9-systematic-review-ejso-2007/>, <https://onco.cc/key-papers/paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008/>, <https://onco.cc/key-papers/paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026/>, <https://onco.cc/key-papers/paper-sausen-ctdna-pancreatic-resection-nat-commun-2015/>, <https://onco.cc/key-papers/paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017/>, <https://onco.cc/key-papers/paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019/>, <https://onco.cc/key-papers/paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019/>, <https://onco.cc/key-papers/paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019/>, <https://onco.cc/key-papers/paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017/>, <https://onco.cc/key-papers/paper-cohen-cancerseek-multi-analyte-blood-test-science-2018/>, <https://onco.cc/key-papers/paper-klein-ccga3-mced-validation-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-gonda-precede-consortium-recommendations-gastroenterology-2021/>, <https://onco.cc/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/>, <https://onco.cc/key-papers/paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019/>, <https://onco.cc/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/>, <https://onco.cc/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/>, <https://onco.cc/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/>, <https://onco.cc/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/>, <https://onco.cc/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/>, <https://onco.cc/key-papers/paper-pishvaian-lancet-oncol/>, <https://onco.cc/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/>, <https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/>, <https://onco.cc/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/>, <https://onco.cc/key-papers/paper-yamamoto-nature/>, <https://onco.cc/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/>, <https://onco.cc/key-papers/paper-bailey-molecular-subtypes-pancreatic-nature-2016/>, <https://onco.cc/key-papers/paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015/>, <https://onco.cc/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/>, <https://onco.cc/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/>, <https://onco.cc/key-papers/paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014/>, <https://onco.cc/key-papers/paper-tempero-ca19-9-lewis-antigens-cancer-res-1987/>, <https://onco.cc/key-papers/paper-fahrmann-ca19-9-lead-time-gastroenterology-2021/>, <https://onco.cc/key-papers/paper-detect-a-science-2020/>, <https://onco.cc/key-papers/paper-canto-caps-long-term-surveillance-gastroenterology-2018/>, <https://onco.cc/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/>, <https://onco.cc/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/>, <https://onco.cc/key-papers/paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018/> ;
  onco:journals <https://onco.cc/journals/journal-of-gastrointestinal-cancer/> ;
  onco:pipeline <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/cmg901/>, <https://onco.cc/drugs/fap-2286/>, <https://onco.cc/technologies/fapi-pet/>, <https://onco.cc/drugs/galleri/>, <https://onco.cc/drugs/satricabtagene-autoleucel/>, <https://onco.cc/drugs/in10018/>, <https://onco.cc/drugs/lm-108/>, <https://onco.cc/drugs/navlimetostat/>, <https://onco.cc/drugs/quemliclustat/>, <https://onco.cc/drugs/gfh375/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/sitneprotafib/>, <https://onco.cc/drugs/setidegrasib/>, <https://onco.cc/drugs/incb161734/>, <https://onco.cc/drugs/trabedersen/>, <https://onco.cc/drugs/qls31905/>, <https://onco.cc/drugs/ivospemin/>, <https://onco.cc/drugs/atebimetinib/>, <https://onco.cc/drugs/ibi343/>, <https://onco.cc/drugs/vs-7375/>, <https://onco.cc/drugs/tng462/>, <https://onco.cc/drugs/xnw27011/>, <https://onco.cc/drugs/e-edv-d682/>, <https://onco.cc/drugs/azd4360/>, <https://onco.cc/drugs/mavrostobart/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/jyp0015/>, <https://onco.cc/drugs/spevatamig/>, <https://onco.cc/drugs/azd5863/>, <https://onco.cc/drugs/ct3001/>, <https://onco.cc/drugs/ponsegromab/>, <https://onco.cc/drugs/jmt203/>, <https://onco.cc/drugs/lp-184/>, <https://onco.cc/drugs/pbp1510/>, <https://onco.cc/drugs/mitazalimab/>, <https://onco.cc/drugs/vb15010/>, <https://onco.cc/drugs/tqb2868/>, <https://onco.cc/drugs/nuv-1511/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/drugs/mrtx1133/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/pairings/g12d-plus-pan-ras/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/technologies/pdac-organoid-pharmacotyping/>, <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/>, <https://onco.cc/ideas/idea-mced-new-onset-diabetes/>, <https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/>, <https://onco.cc/ideas/idea-fap-theranostics-pancancer/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/ideas/idea-pdac-new-onset-diabetes-risk-score-pathway/>, <https://onco.cc/ideas/idea-pdac-surveillance-for-every-germline-carrier/>, <https://onco.cc/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/>, <https://onco.cc/ideas/idea-pdac-stromal-reprogramming-not-depletion/>, <https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/>, <https://onco.cc/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/>, <https://onco.cc/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/>, <https://onco.cc/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/>, <https://onco.cc/ideas/idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway/>, <https://onco.cc/trials/nct07491445/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct07621718/>, <https://onco.cc/trials/nct07805954/>, <https://onco.cc/trials/alliance-a021806/>, <https://onco.cc/trials/preopanc-3/>, <https://onco.cc/trials/nct05968326/>, <https://onco.cc/drugs/elraglusib/>, <https://onco.cc/trials/actuate-1801/>, <https://onco.cc/trials/starpac2/>, <https://onco.cc/trials/nct06608927/>, <https://onco.cc/trials/nct07522073/> ;
  onco:standardOfCare <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/trials/precede/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/trials/panova-3/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/trials/napoli-3/>, <https://onco.cc/trials/polo/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/terms/staging-laparoscopy/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/pancreas-protocol-ct/>, <https://onco.cc/terms/nccn-resectability-criteria-pancreatic/>, <https://onco.cc/terms/pancreatic-enzyme-replacement/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/nutrition-screening-mnt/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/espac-5/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/trials/napoli-3/>, <https://onco.cc/terms/peripheral-neuropathy/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/targets/brca/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/polo/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/terms/stent-or-bypass-for-jaundice/>, <https://onco.cc/terms/biliary-stent-problems/>, <https://onco.cc/terms/acute-cholangitis/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/terms/duodenal-stenting-gastric-outlet/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/enzyme/>, <https://onco.cc/terms/nutrition-impact-symptoms/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/enteral-parenteral-nutrition/>, <https://onco.cc/terms/malnutrition-screening/>, <https://onco.cc/terms/duodenal-stenting-gastric-outlet/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/trials/precede/>, <https://onco.cc/collections/pancan/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/terms/emotional-support-cancer-uk/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/norpact-1/>, <https://onco.cc/trials/swog-s1505/>, <https://onco.cc/trials/neonax/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/preopanc-2/>, <https://onco.cc/trials/alliance-a021806/>, <https://onco.cc/trials/preopanc-3/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/trials/espac-4/>, <https://onco.cc/trials/conko-001/>, <https://onco.cc/drugs/tegafur-gimeracil-oteracil/>, <https://onco.cc/trials/jaspac-01/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/trials/apact/>, <https://onco.cc/trials/espac-5/>, <https://onco.cc/trials/alliance-a021501/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/preopanc-2/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/trials/neolap/>, <https://onco.cc/trials/lap07/>, <https://onco.cc/trials/conko-007/>, <https://onco.cc/trials/scalop/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/mr-linac/>, <https://onco.cc/technologies/irreversible-electroporation/>, <https://onco.cc/trials/crossfire/>, <https://onco.cc/trials/panfire-2/>, <https://onco.cc/trials/panova-3/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-4-accord-11/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/trials/napoli-3/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/trials/mpact/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/trials/panoptimox-prodige-35/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/trials/napoli-1/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/trials/conko-003/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/trials/sequoia/>, <https://onco.cc/trials/trybeca-1/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/polo/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/trials/panoptimox-prodige-35/>, <https://onco.cc/terms/platinum-sensitivity/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/trials/codebreak-100/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/trials/nct03785249/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/trials/nct07621718/>, <https://onco.cc/trials/nct07805954/>, <https://onco.cc/drugs/mrtx1133/>, <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/trials/nct02912949/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-158/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/msi/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/technologies/ttfields/>, <https://onco.cc/trials/panova-3/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/trials/autogene-cevumeran-phase-1/>, <https://onco.cc/trials/nct05968326/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/trials/amplify-7p/>, <https://onco.cc/trials/eclipse/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/shared-antigen-vaccine/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/pancreatic-failed-programmes/>, <https://onco.cc/trials/espac-1/>, <https://onco.cc/trials/halo-301/>, <https://onco.cc/trials/sequoia/>, <https://onco.cc/trials/canstem111p/>, <https://onco.cc/trials/resolve/>, <https://onco.cc/trials/avenger-500/>, <https://onco.cc/trials/lapis-trial/>, <https://onco.cc/trials/trybeca-1/>, <https://onco.cc/trials/impress-trial/>, <https://onco.cc/trials/conko-005/>, <https://onco.cc/trials/lap07/>, <https://onco.cc/trials/conko-007/>, <https://onco.cc/trials/nct05737706/>, <https://onco.cc/trials/amplify-7p/>, <https://onco.cc/trials/norpact-1/>, <https://onco.cc/trials/preopanc-2/>, <https://onco.cc/trials/apact/>, <https://onco.cc/terms/pancreatic-cancer-uk-drug-access/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/institutions/nice/>, <https://onco.cc/terms/pancreatic-palliation-obstruction-pain-nutrition/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/terms/biliary-stent/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/terms/stent-or-bypass-for-jaundice/>, <https://onco.cc/terms/biliary-stent-problems/>, <https://onco.cc/terms/acute-cholangitis/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/terms/pancreatic-palliation-obstruction-pain-nutrition/>, <https://onco.cc/drugs/pancrelipase/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/cancer-associated-thrombosis/>, <https://onco.cc/drugs/ponsegromab/>, <https://onco.cc/trials/nct06989437/>, <https://onco.cc/terms/malnutrition-screening/> .